Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B
Yao-Chun Hsu,Grace Lai-Hung Wong,Chong Chen,Cheng-Yuan Peng,Ming-Lun Yeh,Ka-Shing Cheung,Hidenori Toyoda,Chung-Feng Huang,Huy Trinh,Qing Xie,Masaru Enomoto,Li Liu,Satoshi Yasuda,Yasuhito Tanaka,Ritsuzo Kozuka,Pei-Chien Tsai,Yen-Tsung Huang,Christopher Wong,Rui Huang,Tyng-Yuan Jang,Joseph Hoang,Hwai- Yang,Jiayi Li,Dong-Hyun Lee,Hirokazu Takahashi,Jian Q. Zhang,Eiichi Ogawa,Changqing Zhao,Chenghai Liu,Norihiro Furusyo,Yuichiro Eguchi,Clifford Wong,Chao Wu,Takashi Kumada,Man-Fung Yuen,Ming-Lung Yu,Mindie H. Nguyen
DOI: https://doi.org/10.14309/ajg.0000000000000428
2019-01-01
Abstract:INTRODUCTION: It is unclear whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differ in their effectiveness for preventing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). METHODS: This retrospective cohort study analyzed an international consortium that encompassed 19 centers from 6 countries or regions composed of previously untreated CHB patients then treated with either ETV or TDF monotherapy. Those who developed HCC before antiviral treatment or within 1 year of therapy were excluded. The association between antiviral regimen and HCC risk was evaluated using competing-risk survival regression. We also applied propensity score matching (PSM) to 1:1 balance the 2 treatment cohorts. A total of 5,537 patients were eligible (n = 4,837 received ETV and n = 700 received TDF) and observed for HCC occurrence until December 23, 2018. Before PSM, the TDF cohort was significantly younger and had generally less advanced diseases. RESULTS: In the unadjusted analysis, TDF was associated with a lower risk of HCC (subdistribution hazard ratio [SHR], 0.45; 95% confidence interval [CI], 0.26-0.79; P = 0.005). The multivariable analysis, however, found that the association between TDF and HCC no longer existed (SHR, 0.81; 95% CI, 0.42-1.56; P = 0.52) after adjustment for age, sex, country, albumin, platelet, alpha-fetoprotein, cirrhosis, and diabetes mellitus. Furthermore, the PSM analysis (n = 1,040) found no between-cohort differences in HCC incidences (P = 0.51) and no association between regimens (TDF or ETV) and HCC risk in the multivariable-adjusted analysis (adjusted SHR, 0.89; 95% CI, 0.41-1.92; P = 0.77). DISCUSSION: TDF and ETV did not significantly differ in the prevention of HCC in patients with CHB.